Metastatic RET-mutant medullary thyroid cancer

Drug	Drug Name	Drug Description
DB15685	Selpercatinib	A RET receptor tyrosine kinase inhibitor for the treatment of RET-driven non-small cell lung cancer, medullary thyroid cancer, and thyroid cancer in appropriate patient populations.

Drug	Drug Name	Target	Type
DB15685	Selpercatinib	Proto-oncogene tyrosine-protein kinase receptor Ret	target
DB15685	Selpercatinib	Vascular endothelial growth factor receptor 1	target
DB15685	Selpercatinib	Vascular endothelial growth factor receptor 3	target
DB15685	Selpercatinib	Fibroblast growth factor receptor 1	target
DB15685	Selpercatinib	Fibroblast growth factor receptor 2	target
DB15685	Selpercatinib	Fibroblast growth factor receptor 3	target
DB15685	Selpercatinib	Cytochrome P450 3A4	enzyme
DB15685	Selpercatinib	Cytochrome P450 2C8	enzyme
DB15685	Selpercatinib	Cytochrome P450 3A Subfamily	enzyme
DB15685	Selpercatinib	P-glycoprotein 1	transporter
DB15685	Selpercatinib	ATP-binding cassette sub-family G member 2	transporter
DB15685	Selpercatinib	Multidrug and toxin extrusion protein 1	transporter

Drug	Drug Name	Phase	Status	Count